TRx has entered focussed co-development programmes to establish our technology for small molecules and disease areas with strong relevance to our specific oral targeting benefits.
- Each collaborator molecule has presented multiple significant challenges to best achieve the desired efficacy
- TRx technology is uniquely enhancing both pharmacokinetics and pharmacodynamics to enable progression of each programme
- Recent data generated in each programme is supporting an accelerated path to clinic whilst improving our partners ability to increase IP protection and raise investment
TRx expects three co-development programmes to enter clinical development stages during 2022.